Adelekan D A, Adekile A D, Thurnham D I
Am J Clin Nutr. 1987 Jul;46(1):86-90. doi: 10.1093/ajcn/46.1.86.
The relationship between riboflavin and pyridoxine status was studied in 40 patients with sickle cell disease (SCD) and 12 normal children by measuring activation coefficients of erythrocyte glutathione reductase (EGRAC) and aspartate transaminase (ASTAC). Prevalence of riboflavin deficiency was significantly lower in SCD (42.5%) than in control subjects (83%) and there was less pyridoxine deficiency in SCD (10.3%) than control subjects (54.5%). Aspartate transaminase (AST) activities in SCD patients were double those in control subjects. Pyridoxine status of patients, but not of control subjects, was directly affected by riboflavin status as judged from significant correlations between EGRAC and both AST activity and ASTAC. Poor riboflavin status in patients may be restricting availability of pyridoxal phosphate (PLP) due to combined effects of enhanced PLP requirements and effects of poor riboflavin status on the synthesis of PLP by pyridoxine phosphate oxidase (PPO). PPO activity was no different in the two groups.
通过测量红细胞谷胱甘肽还原酶(EGRAC)和天冬氨酸转氨酶(ASTAC)的激活系数,对40例镰状细胞病(SCD)患者和12名正常儿童的核黄素与吡哆醇状态之间的关系进行了研究。SCD患者核黄素缺乏的患病率(42.5%)显著低于对照组(83%),SCD患者吡哆醇缺乏的情况(10.3%)也少于对照组(54.5%)。SCD患者的天冬氨酸转氨酶(AST)活性是对照组的两倍。从EGRAC与AST活性和ASTAC之间的显著相关性判断,患者而非对照组的吡哆醇状态直接受核黄素状态的影响。患者核黄素状态不佳可能由于对磷酸吡哆醛(PLP)需求增加以及核黄素状态不佳对磷酸吡哆醇氧化酶(PPO)合成PLP的影响的综合作用,限制了PLP的可利用性。两组的PPO活性没有差异。